121 filings
8-K
NRBO
NeuroBo Pharmaceuticals Inc
17 Apr 24
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating
8:30am
8-K
NRBO
NeuroBo Pharmaceuticals Inc
16 Apr 24
Other Events
4:30pm
8-K
NRBO
NeuroBo Pharmaceuticals Inc
1 Apr 24
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
8:30am
8-K
NRBO
NeuroBo Pharmaceuticals Inc
28 Mar 24
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
8:01am
8-K
NRBO
NeuroBo Pharmaceuticals Inc
13 Mar 24
Blinded Safety Review Completed for the First 6 Months of the Phase 2a Clinical Trial Conduct; Recommending Trial Continue Without Modification
8:30am
8-K
x7wlgi0
4 Mar 24
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive
7:30am
8-K
wwo01
29 Feb 24
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
8:30am
8-K
19281
14 Feb 24
Other Events
8:52am
8-K
7o2seqdfyjkliht
1 Feb 24
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
8:30am
8-K
vjo6nf
18 Jan 24
Full Data Readout Expected in the Second Half of 2024
8:30am
8-K
c91ayawis9c86 g05670
9 Jan 24
Other Events
8:45am
8-K
4p5ch
28 Dec 23
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
9:00am
8-K
1vh3msdp1
19 Dec 23
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
9:03am
8-K
dq4klskr8k07gw
7 Dec 23
Regulation FD Disclosure
9:20am
8-K
71knguobycl43kmryfs
13 Nov 23
NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:14pm
8-K
d8w52i9agn7n7q52k
6 Nov 23
Departure of Directors or Certain Officers
8:20am
8-K
8plh2gh muabx
30 Oct 23
Departure of Directors or Certain Officers
8:06am
8-K
2vn7trxiev3xkpblo
22 Sep 23
Regulation FD Disclosure
8:03am
8-K
9c8lmbon tnizt6glwut
19 Sep 23
Departure of Directors or Certain Officers
4:15pm
8-K
7pjscu
15 Sep 23
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
8:11am